ABSTRACT
PE-PilA is a fusion protein composed of immunologically relevant parts of protein E (PE) and the majority subunit of the type IV pilus (PilA), two major antigens of nontypeable Haemophilus influenzae (NTHi). Here we report on the preclinical evaluation of PE-PilA as a vaccine antigen. The immunogenic potential of the PE and PilA within the fusion was compared with that of isolated PE and PilA antigens. When injected intramuscularly into mice, the immunogenicity of PE within the fusion was equivalent to that of isolated PE, except when it was formulated with alum. In contrast, in our murine models PilA was consistently found to be more immunogenic as a subentity of the PE-PilA fusion protein than when it was injected as an isolated antigen. Following immunization with PE-PilA, anti-PE antibodies demonstrated the same capacity to inhibit the binding of PE to vitronectin as those induced after PE immunization. Likewise, PE-PilA-induced anti-PilA antibodies inhibited the formation of NTHi biofilms and disrupted established biofilms in vitro These experiments support the immunogenic equivalence between fused PE-PilA and isolated PE and PilA. Further, the potential of PE-PilA immunization against NTHi-induced disease was evaluated. After intranasal NTHi challenge, colonization of the murine nasopharynx significantly dropped in animals formerly immunized with PE-PilA, and in chinchillas, signs of otitis media were significantly reduced in animals that had received anti-PE-PilA antibodies. Taken together, our data support the use of PE-PilA as an NTHi vaccine antigen.
Subject(s)
Bacterial Proteins/immunology , Fimbriae Proteins/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , Animals , Bacterial Adhesion , Biofilms , Chinchilla , Female , Immunization , Mice , Mice, Inbred BALB C , Nasopharynx/microbiology , Otitis Media/prevention & control , Vaccines, Synthetic/immunology , Vitronectin/metabolismABSTRACT
Pneumococcal adherence to mucosal surfaces is a critical step in nasopharyngeal colonization, but so far few pneumococcal adhesins involved in the interaction with host cells have been identified. PhtA, PhtB, PhtD, and PhtE are conserved pneumococcal surface proteins that have proven promising as vaccine candidates. One suggested virulence function of Pht proteins is to mediate adherence at the respiratory mucosa. In this study, we assessed the role of Pht proteins in pneumococcal binding to respiratory epithelial cells. Pneumococci were incubated with human nasopharyngeal epithelial cells (Detroit-562) and lung epithelial cells (A549 and NCI-H292), and the proportion of bound bacteria was measured by plating viable counts. Strains R36A (unencapsulated), D39 (serotype 2), 43 (serotype 3), 4-CDC (serotype 4), and 2737 (serotype 19F) with one or more of the four homologous Pht proteins deleted were compared with their wild-type counterparts. Also, the effect of anti-PhtD antibodies on the adherence of strain 2737 to the respiratory epithelial cells was studied. Our results suggest that Pht proteins play a role in pneumococcal adhesion to the respiratory epithelium. We also found that antibody to PhtD is able to inhibit bacterial attachment to the cells, suggesting that antibodies against PhtD present at mucosal surfaces might protect from pneumococcal attachment and subsequent colonization. However, the relative significance of Pht proteins to the ability of pneumococci to bind in vitro to epithelial cells depends on the genetic background and the capsular serotype of the strain.
Subject(s)
Bacterial Adhesion/physiology , Bacterial Proteins/physiology , Epithelial Cells/microbiology , Hydrolases/physiology , Streptococcus pneumoniae/physiology , Antibodies, Bacterial/immunology , Antibodies, Monoclonal/immunology , Bacterial Adhesion/immunology , Cell Line, Tumor , Humans , Hydrolases/immunology , Respiratory Mucosa/microbiology , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/pathogenicity , VirulenceABSTRACT
Staphylococcus aureus is an invasive bacterial pathogen, and antibiotic resistance has impeded adequate control of infections caused by this microbe. Moreover, efforts to prevent human infections with single-component S. aureus vaccines have failed. In this study, we evaluated the protective efficacy in rats of vaccines containing both S. aureus capsular polysaccharides (CPs) and proteins. The serotypes 5 CP (CP5) and 8 CP (CP8) were conjugated to tetanus toxoid and administered to rats alone or together with domain A of clumping factor A (ClfA) or genetically detoxified alpha-toxin (dHla). The vaccines were delivered according to a preventive or a therapeutic regimen, and their protective efficacy was evaluated in a rat model of osteomyelitis. Addition of dHla (but not ClfA) to the CP5 or CP8 vaccine induced reductions in bacterial load and bone morphological changes compared with immunization with either conjugate vaccine alone. Both the prophylactic and therapeutic regimens were protective. Immunization with dHla together with a pneumococcal conjugate vaccine used as a control did not reduce staphylococcal osteomyelitis. The emergence of unencapsulated or small-colony variants during infection was negligible and similar for all of the vaccine groups. In conclusion, addition of dHla to a CP5 or CP8 conjugate vaccine enhanced its efficacy against S. aureus osteomyelitis, indicating that the inclusion of multiple antigens will likely enhance the efficacy of vaccines against both chronic and acute forms of staphylococcal disease.
Subject(s)
Antigens, Bacterial/immunology , Bacterial Capsules/immunology , Osteomyelitis/prevention & control , Staphylococcal Infections/prevention & control , Staphylococcal Vaccines/immunology , Staphylococcus aureus/immunology , Animals , Antibodies, Bacterial/immunology , Antigens, Bacterial/administration & dosage , Bacterial Proteins/administration & dosage , Bacterial Proteins/immunology , Disease Models, Animal , Osteomyelitis/immunology , Osteomyelitis/microbiology , Rats , Rats, Wistar , Staphylococcal Infections/immunology , Staphylococcal Infections/microbiology , Staphylococcal Vaccines/administration & dosage , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunologyABSTRACT
Current pneumococcal vaccines are composed of capsular polysaccharides (PS) of various serotypes, either as free PS or as protein-PS conjugates. The use of pneumococcus protein antigens that are able to afford protection across the majority of serotypes is envisaged as a relevant alternative and/or complement to the polysaccharides. In this context, based on several studies, the Pht protein family emerged as relevant vaccine candidates. The purpose of the present study was to evaluate the Pht protein family in several preclinical mouse models. Immunization with these antigens was compared with immunization with other pneumococcal antigens, such as CbpA, PspA, and PsaA. In a nasopharyngeal colonization model and in a lung colonization model, the Phts were found to be superior to the other candidates in terms of efficacy of protection and serotype coverage. Likewise, vaccination with PhtD allowed higher animal survival rates after lethal intranasal challenge. Finally, a passive transfer model in which natural anti-PhtD human antibodies were transferred into mice demonstrated significant protection against lethal intranasal challenge. This indicates that natural anti-PhtD human antibodies are able to protect against pneumococcal infection. Our findings, together with the serotype-independent occurrence of the Phts, designate this protein family as valid candidate antigens to be incorporated in protein-based pneumococcal vaccines.
Subject(s)
Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/immunology , Animals , Antibodies, Bacterial , Drug Evaluation, Preclinical , Female , Immunization, Passive , Mice , Mice, Inbred StrainsABSTRACT
Systems vaccinology has been applied to detect signatures of human vaccine induced immunity but its ability, together with high definition in vivo clinical imaging is not established to predict vaccine reactogenicity. Within two European Commission funded high impact programs, BIOVACSAFE and ADITEC, we applied high resolution positron emission tomography/computed tomography (PET/CT) scanning using tissue-specific and non-specific radioligands together with transcriptomic analysis of muscle biopsies in a clinical model systematically and prospectively comparing vaccine-induced immune/inflammatory responses. 109 male participants received a single immunization with licensed preparations of either AS04-adjuvanted hepatitis B virus vaccine (AHBVV); MF59C-adjuvanted (ATIV) or unadjuvanted seasonal trivalent influenza vaccine (STIV); or alum-OMV-meningococcal B protein vaccine (4CMenB), followed by a PET/CT scan (n = 54) or an injection site muscle biopsy (n = 45). Characteristic kinetics was observed with a localized intramuscular focus associated with increased tissue glycolysis at the site of immunization detected by 18F-fluorodeoxyglucose (FDG) PET/CT, peaking after 1-3 days and strongest and most prolonged after 4CMenB, which correlated with clinical experience. Draining lymph node activation peaked between days 3-5 and was most prominent after ATIV. Well defined uptake of the immune cell-binding radioligand 11C-PBR28 was observed in muscle lesions and draining lymph nodes. Kinetics of muscle gene expression module upregulation reflected those seen previously in preclinical models with a very early (~6hrs) upregulation of monocyte-, TLR- and cytokine/chemokine-associated modules after AHBVV, in contrast to a response on day 3 after ATIV, which was bracketed by whole blood responses on day 1 as antigen presenting, inflammatory and innate immune cells trafficked to the site of immunization, and on day 5 associated with activated CD4+ T cells. These observations confirm the use of PET/CT, including potentially tissue-, cell-, or cytokine/chemokine-specific radioligands, is a safe and ethical quantitative technique to compare candidate vaccine formulations and could be safely combined with biopsy to guide efficient collection of samples for integrated whole blood and tissue systems vaccinology in small-scale but intensive human clinical models of immunization and to accelerate clinical development and optimisation of vaccine candidates, adjuvants, and formulations.
Subject(s)
Adjuvants, Immunologic/metabolism , Fluorodeoxyglucose F18/metabolism , Lymph Nodes/metabolism , Muscles/metabolism , Transcriptome/immunology , Vaccines/metabolism , Adolescent , Adult , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/metabolism , Cytokines/immunology , Female , Humans , Immunization/methods , Kinetics , Lymph Nodes/immunology , Male , Middle Aged , Muscles/immunology , Positron Emission Tomography Computed Tomography/methods , Vaccination/methods , Vaccines/immunology , Young AdultABSTRACT
Biomarkers predictive of inflammatory events post-vaccination could accelerate vaccine development. Within the BIOVACSAFE framework, we conducted three identically designed, placebo-controlled inpatient/outpatient clinical studies (NCT01765413/NCT01771354/NCT01771367). Six antiviral vaccination strategies were evaluated to generate training data-sets of pre-/post-vaccination vital signs, blood changes and whole-blood gene transcripts, and to identify putative biomarkers of early inflammation/reactogenicity that could guide the design of subsequent focused confirmatory studies. Healthy adults (N = 123; 20-21/group) received one immunization at Day (D)0. Alum-adjuvanted hepatitis B vaccine elicited vital signs and inflammatory (CRP/innate cells) responses that were similar between primed/naive vaccinees, and low-level gene responses. MF59-adjuvanted trivalent influenza vaccine (ATIV) induced distinct physiological (temperature/heart rate/reactogenicity) response-patterns not seen with non-adjuvanted TIV or with the other vaccines. ATIV also elicited robust early (D1) activation of IFN-related genes (associated with serum IP-10 levels) and innate-cell-related genes, and changes in monocyte/neutrophil/lymphocyte counts, while TIV elicited similar but lower responses. Due to viral replication kinetics, innate gene activation by live yellow-fever or varicella-zoster virus (YFV/VZV) vaccines was more suspended, with early IFN-associated responses in naïve YFV-vaccine recipients but not in primed VZV-vaccine recipients. Inflammatory responses (physiological/serum markers, innate-signaling transcripts) are therefore a function of the vaccine type/composition and presence/absence of immune memory. The data reported here have guided the design of confirmatory Phase IV trials using ATIV to provide tools to identify inflammatory or reactogenicity biomarkers.
Subject(s)
Biomarkers , Viral Vaccines/adverse effects , Acute-Phase Proteins , Adult , Cytokines/blood , Female , Hematologic Tests , Humans , Male , Symptom Assessment , Transcription, Genetic , Vaccination/adverse effects , Vaccination/methods , Viral Vaccines/immunology , Vital Signs , Young AdultABSTRACT
A clear vision for vaccines research and development (R&D) is needed if Europe is to continue to lead the discovery of next generation vaccines. Innovation Partnership for a Roadmap on Vaccines in Europe (IPROVE) is a collaboration between leading vaccine experts to develop a roadmap setting out how Europe can best invest in the science and technology essential for vaccines innovation. This FP7 project, started in December 2013, brought together more than 130 key public and private stakeholders from academia, public health institutes, regulators, industry and small and medium-sized enterprises to determine and prioritise the gaps and challenges to be addressed to bolster innovation in vaccines and vaccination in Europe. The IPROVE consultation process was structured around seven themes: vaccine R&D, manufacturing and quality control, infrastructure, therapeutic vaccines, needs of small and medium-sized enterprises, vaccines acceptance and training needs. More than 80 recommendations were made by the consultation groups, mainly focused on the need for a multidisciplinary research approach to stimulate innovation, accelerated translation of scientific knowledge into technological innovation, and fostering of real collaboration within the European vaccine ecosystem. The consultation also reinforced the fact that vaccines are only as good as their vaccine implementation programmes, and that more must be done to understand and address vaccination hesitancy of both the general public and healthcare professionals. Bringing together a wide range of stakeholders to work on the IPROVE roadmap has increased mutual understanding of their different perspectives, needs and priorities. IPROVE is a first attempt to develop such a comprehensive view of the vaccine sector. This prioritisation effort, aims to help policy-makers and funders identify those vaccine-related areas and technologies where key investment is needed for short and medium-long term success.
Subject(s)
Biomedical Research/organization & administration , Vaccines , Biomedical Research/economics , Europe , Humans , International Cooperation , InvestmentsABSTRACT
The use of protein antigens able to protect against the majority of Streptococcus pneumoniae serotypes is envisaged as stand-alone and/or complement to the current capsular polysaccharide-based pneumococcal vaccines. Pneumolysin (Ply) is a key virulence factor that is highly conserved in amino acid sequence across pneumococcal serotypes, and therefore may be considered as a vaccine target. However, native Ply cannot be used in vaccines due to its intrinsic cytolytic activity. In the present work a completely, irreversibly detoxified pneumolysin (dPly) has been generated using an optimized formaldehyde treatment. Detoxi-fication was confirmed by dPly challenge in mice and histological analysis of the injection site in rats. Immunization with dPly elicited Ply-specific functional antibodies that were able to inhibit Ply activity in a hemolysis assay. In addition, immunization with dPly protected mice against lethal intranasal challenge with Ply, and intranasal immunization inhibited nasopharyngeal colonization after intranasal challenge with homologous or heterologous pneumococcal strain. Our findings supported dPly as a valid candidate antigen for further pneumococcal vaccine development.
Subject(s)
Antigens, Bacterial/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/immunology , Streptolysins/immunology , Toxoids/immunology , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/administration & dosage , Bacterial Proteins/administration & dosage , Bacterial Proteins/adverse effects , Bacterial Proteins/immunology , Disease Models, Animal , Female , Formaldehyde/metabolism , Male , Mice, Inbred BALB C , Pneumococcal Infections/immunology , Pneumococcal Vaccines/administration & dosage , Rats , Streptolysins/administration & dosage , Streptolysins/adverse effects , Survival Analysis , Toxoids/administration & dosage , Toxoids/adverse effectsABSTRACT
Several vaccines are available against pertussis, differing by the number of Bordetella pertussis antigens that they contain as well as their formulation. The GlaxoSmithKline Biologicals (GSK Bio) tricomponent DTPa vaccine (DTPa3, Infanrix™), and the Sanofi-Pasteur (SP) five-component formulation (DTPa5, Pediacel™) were shown to have comparable short-term efficacy in clinical trials. However, potential differences in long-term protection were recently suggested, which might reflect the elicitation of different specific immune memory by the two vaccines. Therefore, the purpose of the present study was to investigate in mice the immune responses against B. pertussis, and particularly the establishment of specific B cell memory after immunization with DTPa3 and DTPa5 vaccines. Whereas intranasal challenge experiments showed similar protection with both vaccines, DTPa3 induced higher antibody levels to FHA and PRN than DTPa5. Further, the frequency of memory B cells was investigated by B cell ELISPOT. Higher frequencies of PT- and PRN-specific memory B cells were evidenced after vaccination with DTPa3, compared with DTPa5. Although the origin of such difference is unclear, the use of two different adjuvants (aluminum phosphate versus hydroxide) is proposed as a possible explanation. In conclusion, this study proposes that the induction of higher levels of B. pertussis antigen-specific memory B cells with DTPa3 participate to the suggested longer persistence of protection observed with this vaccine, as compared with DTPa5.
Subject(s)
Bordetella pertussis/immunology , Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology , Immunologic Memory , Plasma Cells/immunology , Whooping Cough/prevention & control , Animals , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Female , Immunity, Humoral , Mice , Mice, Inbred BALB C , Whooping Cough/immunologyABSTRACT
In the past years, a significant rise in the proportion of childhood complicated pneumonia cases related to pneumococcal serotypes 1 and 3 has been observed. PhtD is a vaccine candidate protein antigen. By using a pneumococcal lethal intranasal challenge mouse model, a significant additive effect on protection was observed with the combination of vaccination-induced anti-PhtD and injected anti-polysaccharide antibodies specific for serotypes 1 and 3.
Subject(s)
Antibodies, Bacterial/administration & dosage , Antibodies, Bacterial/immunology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/immunology , Streptococcus pneumoniae/immunology , Animals , Antigens, Bacterial/administration & dosage , Antigens, Bacterial/immunology , Bacterial Proteins/administration & dosage , Bacterial Proteins/immunology , Disease Models, Animal , Female , Humans , Mice , Pneumococcal Infections/immunology , Pneumococcal Infections/mortality , Polysaccharides, Bacterial/immunology , Rodent Diseases/immunology , Rodent Diseases/mortality , Rodent Diseases/prevention & control , Streptococcus pneumoniae/pathogenicity , Survival AnalysisABSTRACT
The pneumococcal polysaccharide conjugate vaccine which includes a nonacylated protein D carrier from Haemophilus influenzae has been recently licensed for use in many countries. While this vaccine is protective against nontypeable Haemophilus influenzae (NTHI)-induced acute otitis media (OM), the mechanism underlying this protective efficacy is not yet fully understood. Protein D/glycerophosphodiester phosphodiesterase (PD/GlpQ) is an outer membrane lipoprotein expressed by NTHI that has been ascribed several functions, including host cell adherence and phosphorylcholine (PCho) acquisition. We found that a pd/glpQ NTHI mutant exhibited reduced adherence to airway epithelial cells, diminished phosphorylcholine (PCho) decoration of biofilms, and compromised fitness during experimental acute OM compared to the parent strain. We also found that exposure of NTHI to antibodies directed against the vaccine formulation recapitulated the PCho decoration and NTHI adherence phenotypes exhibited by PD/GlpQ-deficient NTHI, providing at least two likely mechanisms by which the pneumococcal polysaccharide-PD/GlpQ conjugate vaccine induces protection from NTHI-induced OM.
Subject(s)
Bacterial Adhesion , Bacterial Proteins/antagonists & inhibitors , Carrier Proteins/antagonists & inhibitors , Epithelial Cells/microbiology , Haemophilus influenzae/pathogenicity , Lipoproteins/antagonists & inhibitors , Otitis Media/microbiology , Virulence Factors/antagonists & inhibitors , Animals , Bacterial Proteins/genetics , Bacterial Proteins/immunology , Bacterial Proteins/physiology , Carrier Proteins/genetics , Carrier Proteins/immunology , Carrier Proteins/physiology , Chinchilla , Humans , Immunoglobulin D/genetics , Immunoglobulin D/immunology , Immunoglobulin D/physiology , Lipoproteins/genetics , Lipoproteins/immunology , Lipoproteins/physiology , Phosphorylcholine/metabolism , Virulence Factors/genetics , Virulence Factors/immunology , Virulence Factors/physiologyABSTRACT
Infections caused by Streptococcus pneumoniae are a major cause of mortality throughout the world. Protein-based pneumococcal vaccines are envisaged to replace or complement the current polysaccharide-based vaccines. In this context, detoxified pneumolysin (dPly) and pneumococcal histidine triad protein D (PhtD) are two potential candidates for incorporation into pneumococcal vaccines. In this study, the protective efficacy of a PhtD-dPly vaccine was evaluated in a rhesus macaque (Macaca mulatta) model of pneumonia. The animals were immunized twice with 10 µg of PhtD and 10 µg of dPly formulated in the Adjuvant System AS02 or with AS02 alone, before they were challenged with a 19F pneumococcal strain. The survival was significantly higher in the protein-vaccinated group and seemed to be linked to the capacity to greatly reduce bacterial load within the first week post-challenge. Vaccination elicited high concentrations of anti-PhtD and anti-Ply antibodies and a link was found between survival and antibody levels. In conclusion, AS02-adjuvanted PhtD-dPly vaccine protects against S. pneumoniae-induced pneumonia. It is probable that the protection is at least partially mediated by PhtD- and Ply-specific antibodies.
Subject(s)
Antigens, Bacterial/administration & dosage , Antigens, Bacterial/immunology , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/prevention & control , Streptococcus pneumoniae/immunology , Adjuvants, Immunologic/administration & dosage , Animals , Antibodies, Bacterial/blood , Bacterial Load , Bacterial Proteins/administration & dosage , Bacterial Proteins/immunology , Disease Models, Animal , Hydrolases/administration & dosage , Hydrolases/immunology , Immunization, Secondary/methods , Lung/microbiology , Macaca mulatta , Male , Pneumonia, Pneumococcal/immunology , Primate Diseases/immunology , Primate Diseases/prevention & control , Streptolysins/administration & dosage , Streptolysins/immunology , Survival Analysis , Vaccination/methods , Vaccines, Subunit/administration & dosage , Vaccines, Subunit/immunologyABSTRACT
This study examined the vaccine potential of the autotransporter protein BrkA of Bordetella pertussis in the sublethal intranasal murine respiratory challenge model of infection. Five different acellular pertussis (Pa) vaccines, containing different pertussis-component antigens but all comprizing diphtheria (D) and tetanus (T) toxoids, were tested. A two-pertussis-component DTPa vaccine containing pertussis toxoid (PT) and filamentous hemagglutinin (FHA) induced only limited bacterial clearance. However, a three-pertussis-component DTPa vaccine containing PT, FHA and a recombinant BrkA protein (rBrkA) was found to be as efficacious in protecting mice against colonization by B. pertussis strains Tohama I and 18-323 as the commercial Infanrixtrade mark vaccine that also includes PT and FHA but pertactin (PRN) instead of rBrkA. Vaccination of mice with rBrkA as the only B. pertussis antigen did not protect against colonization by B. pertussis. We also demonstrated that BrkA is ubiquitously expressed by highly prevalent clinical isolates of B. pertussis and suggest that new acellular pertussis vaccine formulations that include BrkA have equivalent efficacy as currently available DTPa vaccines against B. pertussis infections.
Subject(s)
Bacterial Outer Membrane Proteins/immunology , Bordetella pertussis/immunology , Lung/immunology , Whooping Cough/prevention & control , Adhesins, Bacterial/immunology , Animals , Bordetella pertussis/growth & development , Colony Count, Microbial , Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology , Female , Lung/microbiology , Mice , Toxoids/immunology , Virulence Factors, Bordetella/immunologyABSTRACT
It has been repeatedly observed that mixing Haemophilus influenzae type b (Hib) conjugate vaccines with acellular pertussis-containing vaccines (diphtheria-tetanus-acellular pertussis [DTPa]) resulted in a reduced magnitude of the anti-polyriboseribitolphosphate antibody response compared to that obtained when Hib vaccines were administered separately and not mixed. Nevertheless, the quality and functionality of the immune responses have been shown to be the same. With the purpose of investigating the quality of the anti-Hib immune responses that are elicited under different vaccination regimens, we report here four primary and booster-based pediatric clinical trials in which Hib vaccine was either mixed with DTPa or diphtheria-tetanus-whole-cell pertussis (DTPw)-based vaccines or was coadministered. Our results show that avidity maturation of the antibodies was lower when primary vaccination involved DTPa mixed with Hib compared to when DTPa and Hib were coadministered. No such difference was observed between mixed and separately administered Hib when associated with DTPa-hepatitis B virus-inactivated poliovirus or DTPw-based vaccines. All different combinations and regimens elicited the same opsonophagocytic and bactericidal activity as well as the same ability to protect in a passive infant rat protection assay. The functional activity of mixed DTPa-based and Hib vaccines was similar to that of mixed DTPw-based/Hib combinations. In conclusion, in vitro and in vivo data as well as postmarketing vaccine effectiveness data attest to the ability of DTPa-based/Hib combination vaccines to effectively prevent Hib-induced disease in children.
Subject(s)
Antibodies, Bacterial/biosynthesis , Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae type b/immunology , Animals , Animals, Newborn , Antibodies, Bacterial/blood , Antibody Affinity , Blood Bactericidal Activity/immunology , Haemophilus Vaccines/administration & dosage , Humans , Immunization, Passive , Immunization, Secondary , Infant , Rats , Vaccines, Combined/administration & dosage , Vaccines, Combined/immunologyABSTRACT
Neisseria meningitidis serogroup B is a major cause of bacterial meningitis in younger populations. The available vaccines are based on outer membrane vesicles obtained from wild-type strains. In children less than 2 years old they confer protection only against strains expressing homologous PorA, a major, variable outer membrane protein (OMP). We genetically modified a strain in order to eliminate PorA and to overproduce one or several minor and conserved OMPs. Using a mouse model mimicking children's PorA-specific bactericidal activity, it was demonstrated that overproduction of more than one minor OMP is required to elicit antibodies able to induce complement-mediated killing of strains expressing heterologous PorA. It is concluded that a critical density of bactericidal antibodies needs to be reached at the surface of meningococci to induce complement-mediated killing. With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection.
Subject(s)
Anti-Bacterial Agents/pharmacology , Antibodies, Bacterial/pharmacology , Membrane Proteins/immunology , Neisseria meningitidis/immunology , Animals , Blood Bactericidal Activity , Drug Synergism , Female , Gene Deletion , Meningococcal Infections/immunology , Meningococcal Infections/prevention & control , Mice , Microbial Viability , Neisseria meningitidis/genetics , Porins/geneticsABSTRACT
Passive transfer of a pediatric human serum pool generated against polysaccharide-protein D conjugate vaccines conferred approximately 34% protection against development of ascending NTHI-induced OM when used in a chinchilla viral-bacterial co-infection model. These data are in line with results obtained using a similar 11-valent-protein D conjugate vaccine in a pediatric clinical trial, wherein a vaccine efficacy of 35.6% was shown against acute OM episodes caused by NTHI. These observations strongly support the chinchilla passive transfer-superinfection model as one that could predict clinical trials outcomes for vaccines to prevent NTHI-induced OM.
Subject(s)
Antibodies, Bacterial/immunology , Bacterial Proteins/immunology , Carrier Proteins/immunology , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , Immunization, Passive , Immunoglobulin D/immunology , Lipoproteins/immunology , Otitis Media/prevention & control , Polysaccharides, Bacterial/immunology , Administration, Intranasal , Animals , Chinchilla , Haemophilus Vaccines/administration & dosage , Humans , Immune Sera/immunology , Nasopharynx/microbiology , Vaccines, Conjugate/immunologyABSTRACT
BACKGROUND: We explored the possibility of using normal adult rhesus macaques for the preclinical assessment of safety, immunogenicity, and efficacy of newly developed vaccines against Streptococcus pneumoniae infection of the lung. METHODS: Our primary objective was to determine whether an intra-bronchial inoculum of at least 10(6)S. pneumoniae colony-forming units, or one as high as 10(8)-10(9) organisms, could detectably survive in rhesus macaques for a period longer than 1-2 weeks. If so, we hypothesized, it would be possible to observe signs of pneumonia commonly observed in humans, and discriminate between vaccinated/protected animals and controls. Infection was detectable in bronchoalveolar lavage fluids 3-5 weeks post-inoculation. RESULTS: The clinical course of disease mimicked aspects of that of human pneumococcal pneumonia. Signs of inflammation typical of the disease in humans, such as elevated concentrations of neutrophils and of pro-inflammatory cytokines in bronchoalveolar lavage fluids were also observed. CONCLUSIONS: These findings underscore the utility of this model to assess the safety, immunogenicity, and efficacy of newly developed S. pneumoniae vaccines.
Subject(s)
Macaca mulatta , Monkey Diseases/immunology , Monkey Diseases/microbiology , Pneumococcal Vaccines/pharmacology , Pneumonia, Pneumococcal/immunology , Pneumonia, Pneumococcal/veterinary , Streptococcus pneumoniae/immunology , Animals , Bronchoalveolar Lavage Fluid/immunology , Bronchoalveolar Lavage Fluid/microbiology , Colony Count, Microbial , Disease Models, Animal , Interleukin-1/metabolism , Interleukin-6/metabolism , Leukocyte Count , Longitudinal Studies , Male , Monkey Diseases/prevention & control , Pneumococcal Vaccines/immunology , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/prevention & control , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Whooping cough remains an endemic disease, and the re-emergence of pertussis in older children and adolescents has been reported in several countries, despite high vaccine coverage. Polymorphism of Bordetella pertussis has been observed over time, and some characteristics of pertussis isolates have gradually diverged from the vaccine strains. The present review summarizes the current knowledge on B. pertussis variability in countries with different vaccination programs and discusses its potential impact on the recently observed increased incidence of whooping cough. No direct association between B. pertussis isolate variability and vaccination programs has been observed to date, except for shifts from fimbriae Fim2 to Fim3. More likely explanations for the re-emergence of pertussis include the change in the epidemiology and transmission patterns of pertussis in highly vaccinated populations, and a shift of disease from young children to adolescents and adults due to waning protective immunity.
Subject(s)
Bordetella pertussis/genetics , Immunization Programs , Pertussis Vaccine , Vaccination , Whooping Cough/prevention & control , Amino Acid Sequence , Bordetella pertussis/immunology , Canada/epidemiology , Europe/epidemiology , Gene Frequency , Humans , Incidence , Molecular Sequence Data , Polymorphism, Genetic , United States/epidemiology , Whooping Cough/epidemiologyABSTRACT
A significant increase in the incidence of pertussis in adolescents and adults has been observed in vaccinated populations. Concomitantly, emergence of novel pertussis toxin and pertactin types in circulating Bordetella pertussis isolates was noticed. In this study, immunity induced by acellular vaccines against infection due to isolates expressing different pertactin types and fimbriae was monitored in a mouse model. In accordance with previous studies, the effect of a bicomponent DTPa vaccine on bacterial clearance was lower when compared with tri- or pentavalent DTPa vaccines. Whatever the isolates used to infect mice, the tri- or pentavalent DTPa vaccines were both efficacious in inducing immunity that resulted in clearance of infection. These findings suggest that re-emergence of pertussis might not be related to emergence of isolates escaping vaccine protection. The present study reduces potential concerns about acellular vaccine efficacy, but frequent monitoring of protection and surveillance of the evolution of the B. pertussis population remains of particular importance.